Clinical Research Directory
Browse clinical research sites, groups, and studies.
Feasibility of Combination Therapy With Low-dose Statin and Ezetimibe in Patients With Minimal Subclinical Atherosclerosis
Sponsor: Yonsei University
Summary
This study aims to compare the tolerability and metabolic safety of three low-dose statin/ezetimibe combinations (rosuvastatin/ezetimibe 2.5/10 mg, atorvastatin/ezetimibe 5/10 mg, pitavastatin/ezetimibe 1/10 mg) in patients with minimal subclinical atherosclerosis identified by imaging studies (Coronary Computed Tomography Angiography, Coronary Angiography, or carotid sonography)
Key Details
Gender
All
Age Range
30 Years - 79 Years
Study Type
INTERVENTIONAL
Enrollment
300
Start Date
2026-11-10
Completion Date
2029-09-21
Last Updated
2026-10-16
Healthy Volunteers
No
Conditions
Interventions
Crezet 2.5/10mg
Participants will take 1 tablet of Rosuvastatin/ezetimibe 2.5/10mg(Crezet 2.5/10mg) orally once daily for 12 months
Litorvazet 5/10mg
Participants will take 1 tablet of Atorvastatin/ezetimibe 5/10mg (Litorvazet 5/10mg) orally once daily for 12 months
Baroezet 1/10mg
Participants will take 1 tablet of Pitavastatin/ezetimibe 1/10mg (Baroezet 1/10mg) orally once daily for 12 months
Locations (2)
Yongin Severance Hospital, Yonsei University College of Medicine
Yongin-si, Gyeonggi-do, South Korea
Yongin Severance Hospital, Yonsei University College of Medicine
Yongin-si, Gyeonggi-do, South Korea